Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro

BACKGROUND: Porcine epidemic diarrhea virus (PEDV) of the family Coronaviridae has caused substantial economic losses in the swine husbandry industry. There’s currently no specific drug available for treatment of coronaviruses or PEDV. METHOD: In the current study, we use coronavirus PEDV as a model...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cui-Cui, Wang, Xiao-Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267768/
https://www.ncbi.nlm.nih.gov/pubmed/32493436
http://dx.doi.org/10.1186/s12985-020-01342-w
_version_ 1783541474122530816
author Li, Cui-Cui
Wang, Xiao-Jia
author_facet Li, Cui-Cui
Wang, Xiao-Jia
author_sort Li, Cui-Cui
collection PubMed
description BACKGROUND: Porcine epidemic diarrhea virus (PEDV) of the family Coronaviridae has caused substantial economic losses in the swine husbandry industry. There’s currently no specific drug available for treatment of coronaviruses or PEDV. METHOD: In the current study, we use coronavirus PEDV as a model to study antiviral agents. Briefly, a fusion inhibitor tHR2, recombinant lentivirus-delivered shRNAs targeted to conserved M and N sequences, homoharringtonine (HHT), and hydroxychloroquine (HCQ) were surveyed for their antiviral effects. RESULTS: Treatment with HCQ at 50 μM and HHT at 150 nM reduced virus titer in TCID(50) by 30 and 3.5 fold respectively, and the combination reduced virus titer in TCID(50) by 200 fold. CONCLUSION: Our report demonstrates that the combination of HHT and HCQ exhibited higher antiviral activity than either HHT or HCQ exhibited. The information may contribute to the development of antiviral strategies effective in controlling PEDV infection.
format Online
Article
Text
id pubmed-7267768
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72677682020-06-03 Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro Li, Cui-Cui Wang, Xiao-Jia Virol J Research BACKGROUND: Porcine epidemic diarrhea virus (PEDV) of the family Coronaviridae has caused substantial economic losses in the swine husbandry industry. There’s currently no specific drug available for treatment of coronaviruses or PEDV. METHOD: In the current study, we use coronavirus PEDV as a model to study antiviral agents. Briefly, a fusion inhibitor tHR2, recombinant lentivirus-delivered shRNAs targeted to conserved M and N sequences, homoharringtonine (HHT), and hydroxychloroquine (HCQ) were surveyed for their antiviral effects. RESULTS: Treatment with HCQ at 50 μM and HHT at 150 nM reduced virus titer in TCID(50) by 30 and 3.5 fold respectively, and the combination reduced virus titer in TCID(50) by 200 fold. CONCLUSION: Our report demonstrates that the combination of HHT and HCQ exhibited higher antiviral activity than either HHT or HCQ exhibited. The information may contribute to the development of antiviral strategies effective in controlling PEDV infection. BioMed Central 2020-06-03 /pmc/articles/PMC7267768/ /pubmed/32493436 http://dx.doi.org/10.1186/s12985-020-01342-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Cui-Cui
Wang, Xiao-Jia
Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title_full Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title_fullStr Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title_full_unstemmed Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title_short Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro
title_sort three kinds of treatment with homoharringtonine, hydroxychloroquine or shrna and their combination against coronavirus pedv in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267768/
https://www.ncbi.nlm.nih.gov/pubmed/32493436
http://dx.doi.org/10.1186/s12985-020-01342-w
work_keys_str_mv AT licuicui threekindsoftreatmentwithhomoharringtoninehydroxychloroquineorshrnaandtheircombinationagainstcoronaviruspedvinvitro
AT wangxiaojia threekindsoftreatmentwithhomoharringtoninehydroxychloroquineorshrnaandtheircombinationagainstcoronaviruspedvinvitro

Ejemplares similares